Scientific Advisory Board

LeadArtis has involved a group of specialists as scientific advisors including experts in immune cell cytotoxic responses and extensive experience in cancer immunotherapy clinical trials sponsored by industry.
 
Luis Álvarez-Vallina, MD, PhD. Co-Founder and scientific advisor. Associate Professor at the Department of Engineering, Immunotherapy and Cell Engineering Laboratory, Aarhus University (Denmark). Luis attended Medical School at Oviedo University (Asturias, Spain) and completed a residency in Immunology at the Clínica Puerta de Hierro (Madrid). Luis earned a PhD in Immunology from the Autónoma University of Madrid (UAM) working on T cell development in the human thymus and spent four years at the Medical Research Council Centre for Protein Engineering (Cambridge, UK) where he worked with Robert E. Hawkins, Stephen J. Russell, and Greg Winter. His work contributed to the first generation of chimeric antigen receptors (CARs) with costimulatory domains. In 1998, he established his research group at the Hospital Universitario Puerta de Hierro (Madrid) focusing on the generation of multispecific antibodies for cancer immunotherapy. His experience includes generation of phage display platforms to select human recombinant antibodies in vivo in tumor-bearing mice (in vivo phage antibody display) and in vitro on complex antigen mixtures expressed on tumor cell surfaces (T lymphocyte display), and the development and preclinical testing of cancer immunotherapy strategies based on the adoptive transfer of genetically engineered cells secreting bispecific antibodies.
 
Ignacio Melero, MD, PhD. Attended Medical School at Navarra University (Pamplona, Spain). He completed a residency in Immunology at the Hospital Universitario de la Princesa (Madrid) and earned a PhD in immunology working on NK receptors. In 1994 he moved to Seattle (USA) where he worked with Karl E. Helström and Lieping Chen in tumor immunology. His work contributed to define immunological ignorance of tumor antigens and, more importantly, contributed decisively to T cell costimulation via CD137/4-1BB. These studies served to discover a potent therapeutic approach using immunostimulatory monoclonal antibodies in rodent models of cancer. In 1998 he returned to Navarra University where he now works at the Clínica Universitaria and at the CIMA research centre. He was appointed full professor of Immunology in 2004 and currently holds this position. Dr. Melero has extensive experience as a principal investigator in clinical trials of cancer immunotherapy both sponsored by industry and by the University of Navarra institutions.
 
Francisco Sanchez-Madrid, PhD. Graduated in Science with honors from the University of Sevilla (Spain) earned a PhD working at the Center for Molecular Biology in Madrid (Spain); soon after, he joined Dr. Timothy A. Springer´s group at Harvard University (Boston, USA), where he studied the cytotoxic response of T lymphocytes and cell adhesion. In 1985, he joined the Immunology Department at the La Princesa University Hospital (Madrid) where currently is the director. Dr. Sanchez-Madrid is author of over 500 peer-reviewed journal articles and patents with seminal contributions in several immunology disciplines including molecular mechanisms that regulate immune cell migration and adhesion, polarization, activation as well as immunological synapse during the regulation of the immune and inflammatory response.
 
Dr. Sanchez-Madrid has been Managing Director of the Spanish Biomedicine Plan (2001-2005), president of the Spanish Health Research Foundation (FIS) Committee on Immunology and Infectious Diseases (1998-2000), member of the European Research Council (ERC) assessment panel (2007-2010), and scientific advisor of numerous Research Institutes. He is a full Professor and chair of Immunology at the Autónoma University of Madrid, a member of several editorial boards, and a full member of the European Molecular Biology Organization (EMBO). In January 2009, he was appointed scientific director of the Health Research Institute of the La Princesa University Hospital.
 
Peter Kristensen, PhD. Dr. Kristensen holds a Master degree in Chemistry and a PhD in Biostructural Chemistry from Aarhus University. In 1995 he moved to Cambridge (UK) to work with Greg Winter at the Medical Research Centre, Laboratory of Molecular Biology and Centre for protein Engineering. The work was centered on establishing new selection methods in protein engineering, especially focusing on selection to optimize enzymatic stability and catalytic properties. In 1998 returned to Aarhus University where he was appointed Associate Professor in 2000 at the Department of Molecular Biology. In 2010, as a result of a large organization change within Aarhus University, he became affiliated with the newly formed Department of Protein Engineering. For a number of years Dr. Kristensen acted as Degree program coordinator for the Biotechnology education, in addition he is chairman of the Research and Innovation Committee at Department of Engineering and member of the PhD committee at Department of Engineering. Dr. Kristensen has developed innovative methods for antibody selection against single rare cells present in a heterogeneous population using phage display. His current research is mainly focused at identifying biomarkers on circulating cancer cells, developing antibodies capable of modulating the vascular system in addition to identifying biomarkers of cells undergoing ageing.
 
Laura Sanz Alcober, MD, PhD. Co-Founder of LeadArtis and a Senior Scientist at the Molecular Immunology Unit in the Hospital Universitario Puerta de Hierro (Madrid). Laura holds a degree in Medicine from the University of Zaragoza and a PhD from the Autónoma University of Madrid (UAM) and completed a postdoctoral fellowship at the Molecular Medicine Program in Mayo Clinic (Rochester, MN, USA) where she specialized in gene transfer, antibody engineering and cancer immunotherapy. Laura has extensive experience with a strong background in Immunology. Over the past years her research group has been focus to identify novel targets and biomarkers of anti-angiogenic therapy.

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)
31-10-2017

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy
15-01-2018

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...